Predictive's CertnDx acquired by PCLS

Looks like this test isn't dead yet. Probably a small asset sale as Predictive was finally being wound down by creditors.


PCLS Announces Acquisition of the CertNDx Bladder Cancer Diagnostic Testing Assets from Predictive Biosciences

30 Apr 2014

Physician’s Choice Laboratory Services (PCLS) is pleased to announce the successful acquisition of the CertNDx Bladder Cancer diagnostic testing assets from Predictive Biosciences. The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test that utilizes protein biomarkers and molecular DNA analysis to detect the presence or absence of urothelial cancer in patients presenting with hematuria.

The test’s unique approach stratifies patients based on their likelihood of bladder cancer and its disease progression. The combination of markers provides both high positive and negative predictive value across all stages and grades of bladder cancer. The result is a test that can assist physicians in providing more effective patient management and personalized care.

According to the National Cancer Institute bladder cancer is the sixth most commonly diagnosed cancer in the US, with nearly 75,000 new cases expected to be diagnosed this year. As with most cancers, early detection is critical to long term survival, especially since bladder cancer has a reoccurrence rate of 50-80 percent and requires life-long surveillance. The most common symptom for bladder cancer is blood in the urine and the diagnostic tool used to determine bladder cancer is acystoscope, which is threaded through the urethra and into the bladder. This is a very uncomfortable procedure and even after diagnosis and treatment patients must go through this procedure every three months for two years and then every six months for the next two years. The CertNDxBladder Cancer Assay detects cancer from urine samples, sparing patients the usual diagnostic discomforts.

"The completion of this acquisition ensures our providers have access to an innovative urine-based diagnostic assay designed to enable physicians to conveniently and reliably determine the presence or absence of bladder cancer," stated Joe Wiegel, president and chief executive officer of PCLS. "Over the coming months, we will continue to execute our clinical development and commercialization plans."